Home » Stocks » Sanofi

Sanofi S.A. (SNY)

Stock Price: $50.50 USD -0.88 (-1.70%)
Updated Aug 14, 2020 12:28 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 126.88B
Revenue (ttm) 44.47B
Net Income (ttm) 3.32B
Shares Out 2.51B
EPS (ttm) 1.94
PE Ratio 26.03
Forward PE 14.71
Dividend $1.70
Dividend Yield 3.37%

Stock Quote

Trading Day Aug 14, 2020
Last Price $50.50
Previous Close $51.37
Change ($) -0.88
Change (%) -1.70%
Day's Open 50.60
Day's Range 50.40 - 50.75
Day's Volume 543,272
52-Week Range 37.62 - 55.00

More Stats

Market Cap 126.88B
Enterprise Value 146.39B
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date Apr 30, 2020
Shares Outstanding 2.51B
Float 2.23B
EPS (basic) n/a
EPS (diluted) 1.94
FCF / Share 3.38
Dividend $1.70
Dividend Yield 3.37%
Earnings Yield 3.84%
FCF Yield 6.66%
Payout Ratio n/a
Shares Short 3.69M
Short Ratio 3.88
Short % of Float n/a
Beta 0.47
PE Ratio 26.03
Forward PE 14.71
P/FCF Ratio 15.01
PS Ratio 2.85
PB Ratio 1.75
Revenue 44.47B
Operating Income 3.69B
Net Income 3.32B
Free Cash Flow 8.45B
Net Cash -19.51B
Net Cash / Share -7.76
Gross Margin 68.18%
Operating Margin 8.30%
Profit Margin 7.50%
FCF Margin 19.01%
ROA 4.00%
ROE 18.62%
ROIC n/a
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (23)

Buy 13
Overweight 3
Hold 7
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$61.01*
(20.82% upside)
Low
50.3
Current: $50.50
High
65.5
Target: 61.01
*Average 12-month USD price target from 19 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue37,63135,67736,22134,69634,86131,99931,29135,95735,05834,036
Revenue Growth5.48%-1.5%4.4%-0.47%8.94%2.26%-12.98%2.56%3%-
Gross Profit25,65524,24224,60823,99523,94221,76920,98924,85924,19324,638
Operating Income3,1254,6765,8046,6665,5716,3674,6686,6225,8466,535
Net Income2,8064,3068,4164,7094,2874,3903,7164,8885,6465,467
Shares Outstanding1,2501,2471,2571,2871,3061,3161,3231,3201,3221,305
Earnings Per Share1.121.723.321.821.631.651.391.842.132.09
EPS Growth-34.99%-48.34%82.92%11.69%-1.52%19.13%-24.73%-13.62%1.91%-
Dividend Per Share1.741.791.051.631.621.911.861.691.321.10
Dividend Growth-2.9%69.92%-35.34%0.74%-15.29%2.58%10.18%28.03%20%-
Operating Cash Flow7,7445,5477,3798,1848,9207,6906,9548,1719,3199,859
Capital Expenditures-592186-1,421-1,874-2,561-1,191-898-1,254-1,423-1,526
Free Cash Flow7,1525,7335,9586,3106,3596,4996,0566,9177,8968,333
Cash & Equivalents9,4276,92510,31510,2739,1487,3418,4426,5594,2976,516
Total Debt25,93324,64015,60118,57916,55414,81414,59014,53115,4398,260
Net Cash / Debt-16,506-17,715-5,286-8,306-7,406-7,473-6,148-7,972-11,142-1,744
Assets112,736111,40899,813104,679102,32197,39296,055100,399100,67285,264
Liabilities53,62852,37341,57446,95744,11141,12439,02242,91344,30931,976
Book Value58,93458,87658,07057,55258,04956,12056,90457,35256,19353,097
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name Sanofi S.A.
Country France
Employees 100,409
CEO Paul Hudson

Stock Information

Ticker Symbol SNY
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NASDAQ: SNY

Description

Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; and Kymera Therapeutics. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.